AXIM® Biotechnologies Announces Additional Purchase Order for Nutraceutical Product With Leading Direct Selling Company

NEW YORK, May 15, 2019 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech”, “AXIM”, or the “Company”), a world leader in cannabinoid research and development, today announced that the company has received an additional purchase order (“PO”) from Kannaway®, the first hemp lifestyle network to offer cannabidiol (“CBD”) hemp, for its cannabinoid-based controlled-release gum nutraceutical product.

The purchase order is a refill of an initial order announced in February 2019 for 7,500 boxes containing 225,000 pieces of AXIM’s cannabinoid-based controlled-release gum. Kannaway® sells AXIM’s formulation as a white label through its direct sales force. Kannaway® has expressed interest in continuing to reorder the gum as its popularity with consumers increases.

“We are delighted to hear that Kannaway’s international consumer base has reacted so well to AXIM’s cannabinoid-based gum formulation,” AXIM® Biotech CEO John W. Huemoeller II said. “With our patent on cannabinoid-based chewing gum, AXIM is proud to serve as Kannaway’s sole supplier of the product as it continues to gain momentum across the globe.”

The product sold under this purchase order is the Company’s nutraceutical cannabinoid-based chewing gum, which contains 50 mg of full-spectrum hemp oil and 10 mg of cannabidiol (“CBD”) per piece.

According to a recent study by Brightfield Group, hemp-derived CBD was a $591 million market in 2018 and expected to reach $22 billion by 2022 after the passing of the 2018 Farm Bill. The product is made using AXIM’s proprietary methodology and utilizes the company’s patented chewing gum delivery system, which allows the CBD to enter the bloodstream more quickly and efficiently through absorption through the buccal cavity. This process increases the bioavailability of the CBD.

“Kannaway’s audience has quickly taken to the new cannabinoid-based chewing gum product that we now offer them and we expect to continue ongoing international sales,” said Kannaway® CEO Blake Schroeder. “AXIM is consistent and reliable in delivering high-quality products for Kannaway to offer to its consumers.”

Kannaway® is a network sales and marketing company specializing in the sales and marketing of hemp-based botanical products.

To learn more about AXIM® Biotechnologies, Inc., visit

About AXIM® Biotechnologies
AXIM® Biotechnologies, Inc. (AXIM) is a world leader in the research and development of cannabinoid-based pharmaceutical and nutraceutical products. Along with building a robust intellectual property portfolio, AXIM is focused on clinical development programs that bring more efficacy and/or lower side effects than existing alternatives and require small to medium budgets and timelines to bring to market which presents a high added-value to the pharmaceutical field.

AXIM's flagship products include MedChew® with dronabinol, which is planned to undergo a bioequivalence study to fast track through FDA as an alternative to approved Marinol; MedChew® RL, which is planned to undergo clinical trials for treatment of restless leg syndrome; and MedChew® Rx, a combination cannabidiol (CBD)/tetrahydrocannabinol (THC) functional, controlled-release chewing gum that is planned to undergo clinical trials for the treatment of pain and spasticity associated with Multiple Sclerosis (MS). For more information, please visit

Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 858-264-6600

Corporate Contact Info:
North American Address:
45 Rockefeller Plaza, 20th Fl.
New York, NY 10111, USA
P. 844 294 6246

European Address:
Industrieweg 40, Unit B4
3401 MA IJsselstein

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of AXIM Biotechnologies, Inc. to be materially different from the statements made herein.

AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).